236 related articles for article (PubMed ID: 15169798)
1. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Kaufman HL; Wang W; Manola J; DiPaola RS; Ko YJ; Sweeney C; Whiteside TL; Schlom J; Wilding G; Weiner LM
J Clin Oncol; 2004 Jun; 22(11):2122-32. PubMed ID: 15169798
[TBL] [Abstract][Full Text] [Related]
2. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW
Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880
[TBL] [Abstract][Full Text] [Related]
5. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Arlen PM; Gulley JL; Todd N; Lieberman R; Steinberg SM; Morin S; Bastian A; Marte J; Tsang KY; Beetham P; Grosenbach DW; Schlom J; Dahut W
J Urol; 2005 Aug; 174(2):539-46. PubMed ID: 16006888
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
[TBL] [Abstract][Full Text] [Related]
7. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
[TBL] [Abstract][Full Text] [Related]
10. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
Doehn C; Kausch I; Böhmer T; Sommerauer M; Jocham D
Curr Opin Mol Ther; 2007 Apr; 9(2):183-9. PubMed ID: 17458173
[TBL] [Abstract][Full Text] [Related]
11. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
12. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
14. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
16. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
18. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]